Leerink Swann & Co

Leerink Swann is bullish on Libigel's prospects for the treatment of female sexual dysfunction.

Leerink Swann is bullish on Libigel's prospects for the treatment of female sexual dysfunction.

Analysts at Leerink Swann & Co upgrade Bio-Rad Laboratories Inc (NYSE: BIO) from "market perform" to "outperform." BIO's shares gained 1.24% to close at $97.72 yesterday. More Analyst Ratings here

Analysts at Leerink Swann & Co initiate coverage of Amicus Theraputics (NASDAQ: FOLD) with a "market perform" rating. FOLD soared 0.60% to close at $3.38 yesterday. More Analyst Ratings here

Analysts at Leerink Swann & Co maintain their "outperform" rating on Merck & Company (NYSE: MRK), while reducing their estimates for the company. According to Leerink Swann & Co, “MRK provided an update on the IMPROVE-IT trial (CV outcome study of Vytorin versus simvastatin in 18,000...

Analysts at Leerink Swann & Co maintain their "outperform" rating on Allergan Inc (NYSE: AGN). Allergan has reported its Q4 EPS marginally ahead of the consensus and inline with the estimates. AGN continues to invest in SG&A and R&D while posting solid results, the analysts say....

Analysts at Leerink Swann & Co maintain their "outperform" rating on Hologic Inc (NASDAQ: HOLX), while raising their estimates for the company. Hologic has reported its F1Q results ahead of expectations. HOLX raised its revenue guidance for FY10 to $1.640B-$1.665B from $1.625B-$1.650B and EPS...

Analysts at Leerink Swann & Co maintain their "market perform" rating on Pharmerica Corporation (NYSE: PMC), while raising their estimates for the company. According to Leerink Swann & Co, Pharmerica has pursued two acquisitions over the past two quarters, which are expected to be accretive...

Analysts at Leerink Swann & Co maintain their "market perform" rating on Valeant Pharmaceuticals (NYSE: VRX), while raising their estimates for the company. According to Leerink Swann & Co, Valeant Pharmaceuticals has issued aggressive guidance for 2010, indicating continued strength in its...

Analysts at Leerink Swann & Co maintain their "outperform" rating on Biogen Idec Inc (NASDAQ: BIIB). According to Leerink Swann & Co, 2010 will be another defining year for BIIB. If Biogen Idec can identify clinically relevant screening assays to predict the risk of PML related to Tysabri,...

Analysts at Leerink Swann & Co maintain their "outperform" rating on Caliper Life Sciences Inc (NASDAQ: CALP), while reducing their estimates for the company. CALP has announced the divestiture of its Xenogen Biosciences subsidiary to Taconic Farms Inc for approximately $11 million. The...